Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Mendus and NorthX Biologics to Enter into Strategic Cell Therapy Manufacturing Alliance Supported by New Investor Flerie
Mendus AB, a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announces that it […]
MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
MEI Pharma, a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, has announced […]
Servier Receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo […]
CytoMed Therapeutics Announces Collaboration with MD Anderson Cancer Center
CytoMed Therapeutics, a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel […]
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community
Actinium Pharmaceuticals, a leader in the development of targeted radiotherapies, today announced that the positive […]
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA
Daiichi Sankyo has announced that the United States Food and Drug Administration (FDA) has extended […]
Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute
Actinium Pharmaceuticals, a leader in the development of targeted radiotherapies, have announced that it has […]
STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML
STORM Therapeutics, the clinical-stage biotechnology company discovering and developing novel small molecule therapies targeting RNA […]
Priothera Announces First Patients Enrolled in Pivotal Global Study for Patients with Acute Myeloid Leukemia
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more